»
«
Offline Showroom in USA
Post Offer Free
MOSINTER GROUP LIMITED
MOSINTER GROUP LIMITED

China Crizotinib CAS 877399-52-5 Crizotinib PF 2341066 Xalkori manufacturer

5th

Gold Index: 89134

You are here: home  > Pharmaceutical Chemicals API  > Antineoplastic Drugs API  > Crizotinib CAS 877399-52-5 Crizotinib PF 2341066 Xalkori

Crizotinib CAS 877399-52-5 Crizotinib PF 2341066 Xalkori 

Payment Terms: T/T,L/C,WU 
Place of Origin: Shandong, China (Mainland) 
inquire skype
Add to My Favorites
HiSupplier Escrow
Share |

Product Detail

Model No.: C21H22Cl2FN5O
Production Capacity: 30Kilogram/Year
Delivery Date: Within 7 days
Molecular Formula: C21H22Cl2FN5O
Specification: CP/USP/EP
Density: 1.475g/cm3
Flashing point: 316.171°C
Means of Transport: Ocean,Land,Air
Packing: According to the request of...
Brand: MOSINTER
Molecular Weight: 450.343
Content: 98%
Boiling point: 599.177°C at 760 mmHg

Crizotinib is currently thought to exert its effects through modulation of the growth, migration, and invasion of malignant cells.

Crizotinib (CAS: 877399-52-5)


Item

Index

Molecular Formula

C21H22Cl2FN5O

Molecular Weight

450.343

Specification

CP/USP/EP

Content

98%

Crizotinib (trade name Xalkori, Pfizer), is an anti-cancer drug acting as an ALK (anaplastic lymphoma kinase) and ROS1 (c-ros oncogene 1) inhibitor, approved for treatment of some non-small cell lung carcinoma (NSCLC) in the US and some other countries, and undergoing clinical trials testing its safety and efficacy in anaplastic large cell lymphoma, neuroblastoma, and other advanced solid tumors in both adults and children.

Mechanism of action

Crizotinib has an aminopyridine structure, and functions as a protein kinase inhibitor by competitive binding within the ATP-binding pocket of target kinases. About 4% of patients with non-small cell lung carcinoma have a chromosomal rearrangement that generates a fusion gene between EML4 ('echinoderm microtubule-associated protein-like 4') and ALK ('anaplastic lymphoma kinase'), which results in constitutive kinase activity that contributes tocarcinogenesis and seems to drive the malignant phenotype. The kinase activity of the fusion protein is inhibited by crizotinib. Patients with this gene fusion are typically younger non-smokers who do not have mutations in either the epidermal growth factor receptor gene (EGFR) or in the K-Rasgene. The number of new cases of ALK-fusion NSLC is about 9,000 per year in theU.S.and about 45,000 worldwide.

ALK mutations are thought to be important in driving the malignant phenotype in about 15% of cases of neuroblastoma, a rare form of peripheral nervous system cancer that occurs almost exclusively in very young children.

Crizotinib inhibits the c-Met/Hepatocyte growth factor receptor (HGFR) tyrosine kinase, which is involved in the oncogenesis of a number of otherhistological forms of malignant neoplasms.

Crizotinib is currently thought to exert its effects through modulation of the growth, migration, and invasion of malignant cells. Other studies suggest that crizotinib might also act via inhibition of angiogenesis in malignant tumors.

bigPhoto
skype Mr. Fedor

Tel: +86-574-89212210
Fax: +86-574-89212215
Mobile: 86- 189 8930 5995
Contact to this supplier

Didn't find what you're looking for? Post Buying Lead or contact HiSupplier Customer Service Center  for help!

Related Search

Find more related products in following catalogs on Hisupplier.com

Other products from this supplier

Company Info

MOSINTER GROUP LIMITED [China (Mainland)]

sgs ico Offline Showroom in USA

Business Type:Manufacturer, Trading Company
City: Ningbo
Province/State: Zhejiang
Country/Region: China (Mainland)

Follow Us: Follow us on facebook Follow us on linkedin

Fedor:   skype

You May Like: